Pharma Should Enlist Patients, Physicians To Fight Off-Label Litigation
Executive Summary
Drug makers should partner with patient advocacy groups and physicians to fight a growing pattern of litigation related to the dissemination of off-label drug information, Sidley Austin Brown & Wood Partner Paul Kalb said during a Drug Information Association workshop Feb. 22 in New York
You may also be interested in...
Off-Label Promotion Cases Need Better Oversight In Justice Dept., WLF Says
Responsibility for coordination of federal off-label promotion investigations should be transferred to the Department of Justice Criminal Division to help ensure appropriate protection of First Amendment rights, the Washington Legal Foundation said in a recent petition to DoJ
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials